CMS To Give More Specifics For Use Of Coverage With Evidence Development
Executive Summary
The Centers for Medicare & Medicaid Services will offer greater clarity on when it will require data collection as a condition of Medicare Part B coverage in a second draft of its guidance on the topic
You may also be interested in...
CMS To Use Coverage With Evidence Development When Rx Benefit Is Likely
The Centers for Medicare & Medicaid Services will use coverage with evidence development only when an agent is highly likely to show benefit in a broader patient population than its labeled indication, CMS Senior Advisor Peter Bach said Dec. 5
Medicare Proposes To Cover J&J’s Natrecor For Labeled Indication Only
The Centers for Medicare & Medicaid Services is proposing to restrict Medicare coverage of Johnson & Johnson/Scios' Natrecor to its labeled indication for acutely decompensated heart failure, rather than provide wider coverage for the drug under a "coverage with evidence development" program
CMS To Use Coverage With Evidence Development When Rx Benefit Is Likely
The Centers for Medicare & Medicaid Services will use coverage with evidence development only when an agent is highly likely to show benefit in a broader patient population than its labeled indication, CMS Senior Advisor Peter Bach said Dec. 5